Cerqua M, Foiani M, Boccaccio C, Comoglio P, Altintas D
EMBO J. 2025; 44(4):1107-1130.
PMID: 39774381
PMC: 11832788.
DOI: 10.1038/s44318-024-00338-4.
Altintas D, Comoglio P
Cancers (Basel). 2023; 15(18).
PMID: 37760640
PMC: 10526818.
DOI: 10.3390/cancers15184672.
Pathmanathan S, Yao Z, Coelho P, Valla R, Drecun L, Benz C
iScience. 2022; 25(11):105419.
PMID: 36388990
PMC: 9646953.
DOI: 10.1016/j.isci.2022.105419.
Altintas D, Gallo S, Basilico C, Cerqua M, Bocedi A, Vitacolonna A
Int J Mol Sci. 2022; 23(20).
PMID: 36293286
PMC: 9604360.
DOI: 10.3390/ijms232012427.
Kim E, Novak L, Lin C, Colic M, Bertolet L, Gheorghe V
Genome Biol. 2022; 23(1):140.
PMID: 35768873
PMC: 9241233.
DOI: 10.1186/s13059-022-02712-z.
Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor.
Desole C, Gallo S, Vitacolonna A, Vigna E, Basilico C, Montarolo F
Front Immunol. 2021; 12:775151.
PMID: 34925346
PMC: 8679783.
DOI: 10.3389/fimmu.2021.775151.
HGF and MET: From Brain Development to Neurological Disorders.
Desole C, Gallo S, Vitacolonna A, Montarolo F, Bertolotto A, Vivien D
Front Cell Dev Biol. 2021; 9:683609.
PMID: 34179015
PMC: 8220160.
DOI: 10.3389/fcell.2021.683609.
State of the structure address on MET receptor activation by HGF.
Linossi E, Estevam G, Oshima M, Fraser J, Collisson E, Jura N
Biochem Soc Trans. 2021; 49(2):645-661.
PMID: 33860789
PMC: 8711257.
DOI: 10.1042/BST20200394.
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib.
Tan A, Loh T, Kwang X, Tan G, Lim K, Tan D
Lung Cancer (Auckl). 2021; 12:11-20.
PMID: 33776501
PMC: 7987308.
DOI: 10.2147/LCTT.S263610.
Inhibitors for the Treatment of Gastric Cancer: What's Their Potential?.
El Darsa H, El Sayed R, Abdel-Rahman O
J Exp Pharmacol. 2020; 12:349-361.
PMID: 33116950
PMC: 7547764.
DOI: 10.2147/JEP.S242958.
Loss of Proprotein Convertase Furin in Mammary Gland Impairs proIGF1R and proIR Processing and Suppresses Tumorigenesis in Triple Negative Breast Cancer.
He Z, Khatib A, Creemers J
Cancers (Basel). 2020; 12(9).
PMID: 32962246
PMC: 7563341.
DOI: 10.3390/cancers12092686.
CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities.
Han K, Pierce S, Li A, Spees K, Anderson G, Seoane J
Nature. 2020; 580(7801):136-141.
PMID: 32238925
PMC: 7368463.
DOI: 10.1038/s41586-020-2099-x.
Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
Miao W, Sakai K, Sato H, Imamura R, Jangphattananont N, Takagi J
Cancer Sci. 2019; 110(10):3340-3349.
PMID: 31342590
PMC: 6778621.
DOI: 10.1111/cas.14142.
Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation.
Frazier N, Brand T, Gordan J, Grandis J, Jura N
Oncogene. 2018; 38(11):1936-1950.
PMID: 30390071
PMC: 6417953.
DOI: 10.1038/s41388-018-0537-0.
Current advances of targeting HGF/c-Met pathway in gastric cancer.
Anestis A, Zoi I, Karamouzis M
Ann Transl Med. 2018; 6(12):247.
PMID: 30069449
PMC: 6046293.
DOI: 10.21037/atm.2018.04.42.
Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy.
Prat M, Oltolina F, Basilico C
Biomedicines. 2017; 2(4):359-383.
PMID: 28548076
PMC: 5344273.
DOI: 10.3390/biomedicines2040359.
Physiological Signaling and Structure of the HGF Receptor MET.
Baldanzi G, Graziani A
Biomedicines. 2017; 3(1):1-31.
PMID: 28536396
PMC: 5344233.
DOI: 10.3390/biomedicines3010001.
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.
Bradley C, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J
Nat Rev Clin Oncol. 2017; 14(9):562-576.
PMID: 28374784
DOI: 10.1038/nrclinonc.2017.40.
Acid sphingomyelinase is required for cell surface presentation of Met receptor tyrosine kinase in cancer cells.
Zhu L, Xiong X, Kim Y, Okada N, Lu F, Zhang H
J Cell Sci. 2016; 129(22):4238-4251.
PMID: 27802163
PMC: 5117200.
DOI: 10.1242/jcs.191684.
Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.
Finisguerra V, Prenen H, Mazzone M
Oncogene. 2016; 35(42):5457-5467.
PMID: 26996670
DOI: 10.1038/onc.2016.36.